Physicians' Academy for Cardiovascular Education
Use of dapagliflozin resulted in rapid clinical benefit in HFrEF patients and risk reduction of the primary outcome by dapagliflozin was largest in patients with a more recent HF hospitalization.
Prof. Rossignol presents results from two mechanistic studies and analyses from two large SGLT2i trials in HFrEF patients that provide insights in the management of diuretics with SGLT2i therapy.
Subgroup analyses from DAPA-HF and EMPEROR-Reduced evaluated the effects of dapagliflozin and empagliflozin on CV and kidney outcomes according to baseline kidney function in patients with HFrEF.
What is the mechanism of action resulting in benefit with SGLT2i? Carlos Santos-Gallego discusses the results of the EMPA-TROPISM trial that shows reverse LV remodeling by empagliflozin in non-diabetic HFrEF.
This exploratory analysis from DAPA-HF showed that dapagliflozin, compared to placebo, reduced new-onset T2DM in patients with HFrEF without diabetes at baseline.
John McMurray and Milton Packer proposed a new algorithm to achieve treatment with a beta-blocker, SGLT2i, ARNI and MRA within 4 weeks in patients with HFrEF.
A risk score based on elevated levels of hs-cTnT, NT-proBNP, and hs-CRP, and presence of left ventricular hypertrophy can stratify incident HF risk in patients with dysglycemia without CVD.
A subanalysis of EMPEROR-Reduced demonstrated that sacubitril/valsartan treatment in patients with HFrEF did not affect risk reducing effects of empagliflozin on HF and kidney events.
A post hoc analysis of patients in the CREDENCE trial with baseline eGFR <30 mL/min/1.73 m² was performed. Prof. Bakris shares the results of this analysis.
The ACC Expert Consensus Decision Pathway (ECDP) for optimization of HFrEF treatment provides practical guidance for physicians in managing patients with HFrEF. The 2017 ECDP has now been updated.
A secondary analysis of EMPA-REG OUTCOME demonstrated that empagliflozin reduced total events of CV outcomes and all-cause admission to hospital compared to placebo in patients with T2DM and ASCVD.
A post-hoc analysis of CANVAS showed that the SGLT2 inhibitor canagliflozin reduced NT-proBNP serum levels in T2DM patients. However, this lowering in NT-proBNP only explained 10% of the reduction on hospitalization by HF by canagliflozin.
